Tag - Bradley Canino

Deciphera Pharma

Stifel cuts Deciphera Pharma to hold; PT to $10 from $60

Stifel downgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) to “hold” from “buy” and slashed its price target to $10 from $60 after the failure of the company’s Qinlock in 2L gastrointestinal stromal tumor (GIST).  Shares...


Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.